Glycoxidative modification of albumin in medical research;Modyfikacje glikooksydacyjne albuminy w badaniach medycznych

Polski Merkuriusz Lekarski

Volumn 34, Issue 202, 2013, Pages 239-242

  Grzebyk, Ewa ^a   Piwowar, Agnieszka ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Glycation; Glycoxidation; Human serum albumin; Oxidation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; FRUCTOSAMINE; ISCHEMIA MODIFIED ALBUMIN; ISCHEMIA-MODIFIED ALBUMIN; SERUM ALBUMIN;

DIABETES MELLITUS; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; REVIEW;

BIOLOGICAL MARKERS; DIABETES MELLITUS; FRUCTOSAMINE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATION-REDUCTION; SERUM ALBUMIN;

EID: 84878144953     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Ahmed N., Argirov O.K., Minhas H.S. et al.: Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Ne-carboxymethyl-lysine and Ne-(1-carboxyethyl)lysine-modified albumin. Biochem. J. 2002, 364, 1-14.
2. Anatelli F., Mroz P., Liu Q. et al.: Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection. Mol Pharm. 2006, 3, 654-664.
3. Anraku M., Kragh-Hansen U., Kawai K. et al.: Validation of the chlorami-ne-T induced oxidation of human serum albumin as a model for oxidative damage in vivo. Pharm. Res. 2003, 20, 684-692.
4. Anraku M., Yamasaki K., Maruyama T. et al.: Effect of oxidative stress on the structure and function of human serum albumin. Pharm. Res. 2001, 18, 632-639.
5. Baraka-Vidot J., Guerin-Dubourg A., Bourdon E. et al.: Impaired drug-binding capacities of in vitro and in vivo glycated albumin. Biochimine 2012; 94; 1960-1967.
6. Castilho G., Okuda L.S., Pinto R.S. et al.: ER stress is associated with reduced ABCA-1 protein levels in macrophages treated with advanced glycated albumin-reversal by a chemical chaperone. Int. J. Biochem. Cell. Biol. 2012; 44; 1078-1086.
7. Colombo G., Clerici M., Giustarini D. et al.: Redox albuminomics: oxidized albumin in human diseases. Antioxid. Redox Signal. 2012; 17; 1515-1527.
8. Diaz N., Suárez D., Sordo T.L. et al.: Molecular dynamics study of the IIA binding site in human serum albumin: influence of the protonation state of Lys195 and Lys199. J. Med. Chem. 2001; 44; 250-260.
9. Fischer D., Bieber T., Brüsselbach S. i et al.: Cationized human serum albumin as a non-viral vector system for gene delivery? Characterization of complex formation with plasmid DNA and transfection efficiency. Int J Pharm. 2001; 225; 97-111.
10. Forbes J. M., Soldatos G., Thomas M. C.: Below the radar: Advanced glycation end products that detour., around the side". Clin. Biochem. Rev. 2005; 26; 123-134.
11. Gałecka E., Mrowicka M., Malinowska K. i wsp.: Wolne rodniki tlenu i azotu w fizjologii. Pol. Merk. Lek. 2008; 24; 446-448.
12. Iwao Y., Anraku M., Hiraike M. et al.: The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP). Drug Metab. Pharmacokinet. 2006; 21; 140-146.
13. Kagan V.E., Tyurin V.A., Borisenko G.G. et al.: Mishandling of cooper by albumin: role in redox-cycling and oxydative stress in preeclampsia plasma. Hypertens. Preg. 2001; 20; 221-241.
14. Kawakami A., Kubota K., Yamada N. et al.: Identification and characterization of oxidized human serum albumin. A slight structural change impairs its ligand-binding and antioxidant functions. FEBS J. 2006; 273; 3346-3357.
15. Knapik-Kordecka M., Piwowar A., Zurawska-Płaksej E. i wsp.: Albumina modyfikowana niedokrwieniem-specyficzny marker w diagnostyce kar-diologicznej? Wiad. Lek. 2008; 61; 263-268.
16. Matejtschuk P., Dash C.H., Gascoigne E.W.: Production of human albumin solution: a continually developing colloid. Br. J. Anaesth. 2000;85,;887-895.
17. Matough F.A., Budin S.B., Hamid Z.A. et al.: The role of oxidative stress and antioxidants in diabetic complications. Sultan. Qaboos. Univ. Med. J. 2012; 12; 5-18.
18. Mendez D.L., Jensen R.A., McElroy L.A. et al.: The effect of non-enzymatic glycation on the unfolding of human serum albumin. Arch. Biochem. Biophys. 2005; 444; 92-99.
19. Myszka W., Wysocka E., Torlinski L.: Albumina modyfikowana niedokrwie-niem i test wiazania kobaltu przez albumine-charakterystyka nowych terminów w diagnostyce biochemicznej niedokrwienia miesnia sercowe-go. Diagn. Lab. 2006; 42; 223-233.
20. Oettl K., Stauber R.E.: Physiological and pathological changes in the re-dox state of human serum albumin critically influence its binding properties. Br. J. Pharm. 2007; 151; 580-590.
21. Peters T. Jr.: All about albumin: Biochemistry, genetics and medical applications. Academic Press San Diego, CA 1996; 79-123, 228-240, 251-256, 260-277, 283, 305-336.
22. Piwowar A.: Zaawansowane produkty utleniania białek. Czesc I. Mechanizm powstawania, struktura i własciwosci. Pol. Merk. Lek. 2010; 28; 166-169.
23. Rutkowski R., Pancewicz S.A., Rutkowski K. i wsp.: Znaczenie reaktyw-nych form tlenu i azotu w patomechanizmie procesu zapalnego. Pol. Merk. Lek. 2007; 23;-136.
24. Sakata N., Moh A., Takebayashi S.: Contribution of superoxide to reduced antioxidant activity of glycoxidative serum albumin. Heart Vessels. 2002; 17: 22-29.
25. Sattarahmady N., Moosavi-Movahedi A.A., Ahmad F. et al.: Formation of the molten globule-like state during prolonged glycation of human serum albumin. Biochim. Biophys. Acta. 2007; 1770; 933-942.
26. Sattarahmady N., Moosavi-Movahedi A.A., Habibi-Rezaei M. et al.: De-tergency effects of nanofibrillar amyloid formation on glycation of human serum albumin. Carbohydr. Res. 2008; 343; 2229-2234.
27. Seneviratne C., Narayanan R., Liu W. et al.: The in vitro inhibition effect of 2 nm gold nanoparticles on non-enzymatic glycation of human serum albumin. Biochem. Biophys. Res. Commun. 2012; 422; 447-454.
28. Sharp P. S., Rainbow S., Mukherjee S.:Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet. Med. 2003; 20; 575-579.
29. Singh R., Barden A., Mori T. et al.: Advanced glycation end-products: a review. Diabetologia 2001; 44; 129-146.
30. Styszynski A., Korybalska K., Wieczorowska-Tobis K.: Nieenzymatyczna gli-kozylacja białek-potencjalna rola w patogenezie chorób i starzeniu. http://www.zdrowezywienie.yoyo.pl/articles.php?id=11 (dostep: 15.04.2010).
31. Subramaniam R., Fan X.-J., Scivittaro V. et al.: Cellular oxidant stress and advanced glycation endproducts of albumin: caveats of the dichloro-fluorescein assay. Arch. Biophem. Biophys. 2002; 400; 15-25.
32. Tarwadi K.V., Agte V.V.: Effect of micronutrients on methylglyoxal- mediated in vitro glycation of albumin. Biol. Trace. Elem. Res. 2011; 143; 717-725.
33. Tkachev S.V., Ushkov A.A.: Role of Cu2+ in free radical oxidation of human serum albumin and L-tyrosine dipeptide with multicomponent metal-containing xenobiotic. Exp. Biol. Med. 2005; 140; 309-311.
34. Traverso N., Menini S., Cottalasso D. et al.: Mutual interaction between glycation and oxydation during non-enzymatic protein modyfication. Bio-chim. Biophys. Acta 1997; 1336; 409-418.
35. Trynda-Lemiesz L., Wiglusz K., Mucha I.: Rola albuminy w diagnostyce. Wiazanie jonów i kompleksów metali. Wiad. Chem. 2010; 64; 81-104.
36. Vlková B., Stanko P., Minárik G. et al.: Salivary markers of oxidative stress in patients with oral premalignant lesions. Arch. Oral. Biol. pii: S0003-9969(12)00324-X. doi: 10.1016/j.archoralbio.2012.09.003. [Epub ahead of print]
37. Wa C., Cerny R.L, Clarke W.A. et al.: Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chim. Acta 2007; 385; 48-60.
38. Witko-Sarsat V., Nguyen-Khoa T., Jungers P. et al.: Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Nephrol. Dial. Transplant. 1999; 14; 76-78.
39. Zheng C.M., Ma W.Y., Wu C.C. et al.:Glycated albumin in diabetic patients with chronic kidney disease. Clin. Chim. Acta 2012; 413; 1555-15561.